Medicines Patent Pool

MPP and TB Alliance sign Memorandum of Understanding to support further development of sutezolid

Geneva, 31 October 2017 — The Medicines Patent Pool (MPP) and TB Alliance signed a Memorandum of Understanding (MoU) to facilitate third-party development of sutezolid-containing tuberculosis regimens. The MoU follows the sublicensing agreement signed by both organisations in March 2017 granting TB Alliance the rights to develop sutezolid, a promising antibiotic drug candidate, in combination with other TB drugs for drug-susceptible and drug-resistant TB patients.

Read More →

The Medicines Patent Pool and Otsuka sign Memorandum of Understanding for paediatric formulations of delamanid for multidrug-resistant TB

Geneva, 11 October 2017 — The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB).

Read More →

MPP video: Working together for better treatment options

The Medicines Patent Pool (MPP) released a short film, in which MPP’s stakeholders from industry, government, civil society and patient groups discuss the foundation’s innovative business model, achievements and future plans to increase access to HIV, hepatitis C and TB treatment within the context of the UN Sustainable Development Goals.

Read More →

TB Alliance sublicenses promising TB drug from the Medicines Patent Pool

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer.

Read More →

Medicines Patent Pool’s next steps in TB: stewardship report

In the context of its mandate expansion into tuberculosis, the Medicines Patent Pool (MPP) was asked by its funder, UNITAID, to conduct a study to examine how MPP licences could contribute to addressing some of the stewardship challenges for new drugs for tuberculosis, specifically for multidrug-resistant TB. The report seeks to inform the Foundation’s approach to negotiating licences and sub-licences for the manufacturing of TB compounds. It acknowledges the twin public health goals of ensuring broad availability of new therapies while promoting their proper use to counter further resistance.

Read More →

Medicines Patent Pool announces MedsPaL: its new Medicines Patents & Licences Database

Medicines Patent Pool's signature database upgraded to include patent and licensing data for HIV, hepatitis C and TB medicines.

Read More →

The Medicines Patent Pool expands mandate to hepatitis C and tuberculosis treatment

TB is the leading cause of death for people living with HIV and killed 1.5 million people globally in 2014 alone. TB treatment has become more complex, particularly with the emergence of multidrug-resistant strains of TB. The Medicines Patent Pool, the world’s only voluntary licensing mechanism in public health, will now work to ensure access to new treatments for drug-resistant and drug-susceptible TB.

Read More →

The Medicines Patent Pool releases independent feasibility studies on hepatitis C and tuberculosis

As part of its ongoing consultation processes on the possibility of the Medicines Patent Pool (MPP) expanding into other disease areas, the organisation has published independent feasibility studies exploring the case for potential entry into hepatitis C and tuberculosis.

Read More →

The Medicines Patent Pool statement on potential extension of its mandate to hepatitis C and tuberculosis

The MPP acknowledges the recent response and input from various civil society organisations and treatment groups on the Foundation’s ongoing assessments to determine the feasibility of extending its mandate to include medicines for hepatitis C (HCV) and tuberculosis (TB).

Read More →

MPP strategic expansion consultancy – tuberculosis

The Medicines Patent Pool (MPP) is seeking proposals from individuals and organisations to assess the feasibility of expanding the mandate of the MPP into tuberculosis (TB). The proposed timeframe for the provision of the consultancy services is 15th November 2014 to 27th February 2015.

Read More →

Page 1 of 2 · Total posts: 10

1 2 Last→